Back to News
Market Impact: 0.15
Moleculin Biotech, Inc. Announces Acceptance of Annamycin Data for Presentation at the 2026 American Society of Hematology (ASH) Annual Meeting
Source: Nasdaq
Healthcare & Biotech
Moleculin Biotech said an abstract featuring data on its lead drug candidate, Annamycin, was accepted for presentation at the 2026 ASH Annual Meeting, scheduled for December 12–15 in New Orleans. The article excerpt provides no study results or efficacy figures.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.15
Ticker Sentiment
MBRX0.40
More News
- We're raising our price target on Cardinal Health after another stellar quarter of profits
- Halozyme falls 6% as raised guidance fails to impress investors
- Dentsply earnings missed by $0.02, revenue fell short of estimates
- US hospitals brace for tougher 2027 as coverage losses and Medicaid cuts loom
- Cigna raises annual profit forecast on strength in health services unit
- Truist raises Zimmer Biomet stock price target on robotics progress